{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Certolizumab+Pegol&page=4", "query": { "intervention": "Certolizumab Pegol", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 85, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Certolizumab+Pegol&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Certolizumab+Pegol&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T12:58:24.889Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02497976", "title": "Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystitis, Interstitial" ], "interventions": [ { "name": "Certolizumab pegol", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "ICStudy, LLC", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 42, "start_date": "2015-12-15", "completion_date": "2017-07-12", "has_results": true, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-10-10T12:58:24.889Z", "location_count": 1, "location_summary": "Escondido, California", "locations": [ { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02497976" }, { "nct_id": "NCT04772248", "title": "Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tofacitinib", "type": "DRUG" }, { "name": "TNF Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105711, "start_date": "2021-02-22", "completion_date": "2021-12-30", "has_results": false, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-10T12:58:24.889Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04772248" }, { "nct_id": "NCT00333788", "title": "Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Certolizumab pegol (CDP870)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 233, "start_date": "2006-10", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-10-10T12:58:24.889Z", "location_count": 19, "location_summary": "Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 16 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00333788" }, { "nct_id": "NCT00160641", "title": "A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 567, "start_date": "2005-11", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-10-10T12:58:24.889Z", "location_count": 12, "location_summary": "Palm Desert, California • Pasadena, California • Santa Maria, California + 9 more", "locations": [ { "city": "Palm Desert", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Naples", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00160641" }, { "nct_id": "NCT03414502", "title": "Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 400, "start_date": "2007-12-10", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-10T12:58:24.889Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414502" }, { "nct_id": "NCT04740814", "title": "A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Certolizumab pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 33, "start_date": "2021-02-11", "completion_date": "2022-06-27", "has_results": true, "last_update_posted_date": "2024-02-12", "last_synced_at": "2026-10-10T12:58:24.889Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Covina, California • Upland, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04740814" }, { "nct_id": "NCT01582568", "title": "EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Crohns Disease" ], "interventions": [ { "name": "Certolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1, "start_date": "2011-06", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2016-02-19", "last_synced_at": "2026-10-10T12:58:24.889Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01582568" }, { "nct_id": "NCT06028438", "title": "A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Nipocalimab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 103, "start_date": "2023-08-15", "completion_date": "2024-10-29", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-10T12:58:24.889Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Huntington Beach, California • Upland, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Brandon", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06028438" }, { "nct_id": "NCT00160602", "title": "A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2005-06", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2020-12-01", "last_synced_at": "2026-10-10T12:58:24.889Z", "location_count": 17, "location_summary": "Montgomery, Alabama • Sun City West, Arizona • Palm Desert, California + 14 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Sun City West", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00160602" }, { "nct_id": "NCT02346240", "title": "Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Plaque Psoriasis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Etanercept", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 559, "start_date": "2015-02-11", "completion_date": "2018-12-17", "has_results": true, "last_update_posted_date": "2021-07-16", "last_synced_at": "2026-10-10T12:58:24.889Z", "location_count": 19, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02346240" } ] }